Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Duchenne Muscular Dystrophy
Conditions
Duchenne Muscular Dystrophy
Trial Timeline
Apr 26, 2023 → Feb 1, 2025
NCT ID
NCT05753462About Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3) is a phase 1/2 stage product being developed by Biotrial for Duchenne Muscular Dystrophy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05753462. Target conditions include Duchenne Muscular Dystrophy.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05753462 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Duchenne Muscular Dystrophy